Orvar™ Autoantigen Discovery Technology

Orvar™ Autoantigen Discovery Technology

Using conventional methods, it would be necessary to screen every single human protein, splice variant, neoantigen or microbial antigen to discover the total repertoire of autoantigens within a disease.

By using the Orvar™ Autoantigen Discovery Technology, the identity of all the autoantigens and antigens that make up the Autoproteome™ can be discovered. The Autoproteome™ is defined as the totality of autoantigens and antigens within a human at any one time the individual may or may not have the disease.

Orvar™ identifies all possible autoantigens and antigens within a human at a given time which are associated with a disease.

Once the Autoproteome™ is identified, we then use our patented KREX™ technology to clone, express and attach every single autoantigen or antigen on to a Sengenics protein array. This customised protein array then serves as a validated, true positive antigen and autoantigen library which is disease-specific. Applications for this protein array include the discovery of autoantibodies for characterisation of diseases either as biomarkers for early diagnostics, protective autoantibodies or intra-disease stratification.

Orvar™ Case Study

Colorectal Cancer

Study Design:

  • Sample type:
    • Plasma from Colorectal cancer and healthy normal individuals
    • Tissue from Colorectal cancer individuals (cancer and adjacent normal tissue)
  • Platform:
    • Sengenics KREX CT100+ microarray
    • Orvar™ Autoproteome™ Discovery technology

Results:

Breakdown of Selected/Identified Antigens

Figure 1: Distribution and classification of the top antigens identified in both experiments



  • Non wild-type autoantigens – Positive results on Orvar™ only



  • Autoantigens unique to Orvar™ – Autoantigens not found on KREX microarray



  • Homologue autoantigens – Matched positive results between Orvar™ and KREX microarray



  • Wild-type autoantigens – Matched positive results between Orvar™ and KREX microarray

  • The Orvar™ technology identified a total of 28 unique autoantigens (Figure 2) which had corresponding autoantibodies present in Colorectal cancer patients;
  • This Orvar™ Colorectal library also led to the discovery of homologues to the antigens eliciting high autoantibody responses on KREX microarrays. These homologues may contain overlapping surface epitopes reactive to these autoantibodies;
  • As all antigens immobilised onto the KREX microarrays are present as wild-type forms, the unique antigens on Orvar™ which are also on KREX microarrays suggests detection of mutated forms of these antigens using the Orvar™ technology.

Figure 2: GO enrichment analysis for the top 28 unique autoantigens identified using Orvar™

FEATURED PRODUCTS

IMMUNOME Protein Array

High-throughput multiplexed autoantibody screening protein array containing 1600+
autoantigens

ImmuSAFE COVID Tests

Contains correctly folded antigens from SARS-CoV-2 and 25 other Corona and Influenza
viruses

SARS-CoV-2 Antigens

7 Recombinant SARS-CoV-2 antigens expressed using the patented KREX™ functional proteomics technology

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

2008 – 2020© Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

X